Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 1,300,000 shares, a growth of 5.7% from the August 15th total of 1,230,000 shares. Based on an average daily trading volume, of 174,700 shares, the days-to-cover ratio is presently 7.4 days. Currently, 3.1% of the company’s stock are sold short.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on AURA shares. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Aura Biosciences in a research note on Friday. JMP Securities increased their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday. Finally, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th.
Read Our Latest Stock Report on Aura Biosciences
Institutional Trading of Aura Biosciences
Aura Biosciences Trading Down 1.0 %
AURA opened at $9.97 on Tuesday. The stock has a fifty day moving average price of $8.58 and a 200 day moving average price of $7.87. Aura Biosciences has a 1 year low of $5.99 and a 1 year high of $12.35. The stock has a market cap of $493.94 million, a price-to-earnings ratio of -5.36 and a beta of 0.35.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. As a group, sell-side analysts forecast that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.
Aura Biosciences Company Profile
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Read More
- Five stocks we like better than Aura Biosciences
- How to Calculate Options Profits
- Market Got It Wrong—Why Progress Software Deserves a Second Look
- Conference Calls and Individual Investors
- PENN Entertainment Eyes ESPN BET to Score Big in 2024 NFL Season
- How to Invest in Blue Chip Stocks
- Don’t Miss Out: NETGEAR’s Turnaround Signals Big Potential
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.